BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:In an era marked by remarkable advancements\, the inhalation t
 herapy field is rapidly evolving. From Avalyn's $175 million investment i
 n inhaled pulmonary fibrosis trials to Krystal Biotech's FDA clearance fo
 r inhaled gene therapy and MIT engineers' work on inhaled nanoparticles\,
  the field is abuzz with new advances and breakthroughs in inhalation del
 ivery.\n\nRight now\, we explore inhaled therapies as an opportunity to r
 e-purpose modalities to tackle unmet clinical need in diseases like COPD\
 , asthma\, IPF\, emphysema\, and lung cancer\, to unlock therapeutic effi
 cacy. Now is the time for the industry to unite and innovate solutions to
  challenges surrounding particle engineering\, stability\, and formulatio
 n-device compatibility. Immerse yourself in a wealth of knowledge at the 
 2nd Next Gen Inhalation Delivery Summit\, as the only forum offering cutt
 ing edge\, future focused updates for inhaled delivery of complex biologi
 cs\, maintaining formulation integrity to achieve precise lung delivery.\
 n\nThis is the premier forum dedicated to inhalation's future\, providing
  crucial insights and networking opportunities. Join us in June to stay a
 head in optimizing lung-specific drug delivery for maximum efficacy and p
 otency in non-invasive\, localized delivery.\n\nDate and Time: Tuesday\, 
 04 June 2024 at 07:30 to Thursday\, 06 June 2024 at 17:00\n
DTEND:20240606T170000
DTSTAMP:20260512T232945Z
DTSTART:20240604T073000
LOCATION:Hilton Boston Logan Airport\, One Hotel Drive\, Boston\, Massachu
 setts\, 02128\,
SEQUENCE:0
SUMMARY:In an era marked by remarkable advancements\, the inhalation thera
 py field is rapidly evolving. From Avalyn's $175 million investment in in
 haled pul...
UID:a260edd4-0f30-41ed-918c-7164b408bbb3
END:VEVENT
END:VCALENDAR